Intervention to Improve the Delivery of Follow-up Care for Low-Risk Breast Cancer

Evaluating a Novel Follow-up Intervention to Improve the Delivery of Follow-up Care for Low-Risk Breast Cancer Survivors in Wisconsin

This study tests a novel intervention designed to optimize needed survivorship care for low-risk breast cancer survivors while reducing burdensome care with limited health benefits. This study examines whether the intervention, titled REASSURE, improves survivors' preparedness for survivorship. Up to 110 participants will be on study for up to 18 months.

Study Overview

• Status: Completed
• Conditions: Breast Cancer
• Intervention / Treatment: Other: REASSURE

Detailed Description

The investigators plan a single site prospective, randomized, trial that will compare the effect of REASSURE on survivor preparedness against usual care. Survivors will be identified from breast oncology clinics within UW Health.

REASSURE is comprised of three components: 1) the REASSURE PRO assessment, which assesses survivors' symptoms and/or concerns, 2) a recommendation for or against a follow-up visit based on survivors reported symptoms /concerns using pre-established thresholds, and 3) REASSURE survivorship messaging.

• Primary Objective

  • Compare survivors' preparedness for survivorship with REASSURE versus usual care.

• Secondary Objectives

  • Determine the acceptability of REASSURE for survivors living in rural and non-rural areas.
  • Assess changes in survivor reported symptoms and number of follow-up visits with REASSURE versus usual care.

• Study Type: Interventional
• Enrollment (Actual): 104
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Wisconsin
    • Madison, Wisconsin, United States, 53792
      • UW Health Oncology Clinics

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 95 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Diagnosis of stage I, ER and/or PR positive, her2neu negative breast cancer within the last 6-24 monoths
• Willing to complete study procedures using email

Exclusion Criteria:

• Receipt of chemotherapy for the stage I ER and/or PR positive, her2neu negative breast cancer diagnosed within the last 6-24 months
• Participants will be excluded if they are unable to read and write in English or if, in the opinion of a treating clinician, have cognitive impairment that would prevent completion of study procedures
• Pregnancy, based on patient self-report. If a patient becomes pregnant during the study period, they will be removed from the study at that time.
• Diagnosis of a ER and PR negative, her2neu negative breast cancer or a her2neu positive breast cancer within the last 5 years

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: REASSURE Follow Up care	Other: REASSURE; REASSURE is comprised of three components that are intended to be integrated into survivorship care at each follow-up visit: 1) An online patient-reported outcome (PRO) assessment to comprehensively evaluate survivors' symptoms and concerns; 2) A tailored follow-up recommendation based on pre-established thresholds for reported symptoms and concerns. Survivors who report symptoms or concerns have a follow-up visit to discuss findings whereas survivors without symptoms or concerns will avoid a follow-up visit; and 3) Online survivorship messaging sent after the visit, which includes reassurance about the low recurrence risk, an overview of what to expect from follow-up, and steps survivors can take to reduce cancer risk.
No Intervention: Usual Follow Up Care

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Preparing for Life as a (New) Survivor (PLANS) Scale Score: Part 1	Survivors' preparedness for survivorship will be assessed using Part 1 of the Preparing for Life as a (New) Survivor (PLANS) scale. This is an 11-item survey scored on a 4 point likert scale for a total possible range of score from 11 - 44 where higher scores indicate increased preparedness.	up to 18 months
Preparing for Life as a (New) Survivor (PLANS) Scale Score: Part 2	Survivors' confidence about follow-up will be assessed using Part 2 of the Preparing for Life as a (New) Survivor (PLANS) scale. This is a 5-item survey scored on a 10 point likert scale for a total possible range of score from 5 - 50 where higher scores indicate increased confidence.	up to 18 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants In Intervention Arm who would recommend this approach to follow-up to other survivors	REASSURE will be considered acceptable if ≥80% of survivors in the REASSURE arm respond "yes" to, "Would you recommend this approach to follow-up to other survivors?".	up to 18 months
Number of Threshold-Level Symptoms Reported on the PRO Assessment	The number of threshold-level symptoms reported on the Patient Reported Outcome (PRO) assessment at each follow-up time point will be reported. This is based on the investigators' previously established thresholds of symptoms or concerns that warrant a visit. Some symptoms were "hard stops", meaning any reported symptom triggered a visit, other symptoms triggered a visit based on severity or level of interference.	up to 18 months
Number of Threshold-Level Symptoms Survivors Perceive are Addressed on each visit		up to 18 months
Number of Follow Up Visits	The number of follow-up visits over the 18-month follow-up period will be counted. All follow-up visits that occur in medical oncology, radiation oncology, surgery, and survivorship clinics, including both physician and advanced practice provider visits will be counted.	up to 18 months

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants Who Received Recommended Cancer Care	Receipt of recommended cancer care over 18-months (chart review, yes/no)	up to 18 months
Survivors' Experiences: Impact of Event Scale	Impact of Event Scale (measure of cancer-related anxiety) is a 15-item survey scored on a 5 point likert scale for a total possible range of scores from 15-75 where higher scores indicate higher anxiety.	up to 18 months
Survivors' Experiences: Satisfaction with Information	Satisfaction with Information is measured using a 14-item survey scored on a 5 point likert scale for a total possible range of scores from 14-70 where higher scores indicate increased satisfaction with information.	up to 18 months
Survivors' Experiences: Human Connection Scale Score	Human Connection Scale (measure of therapeutic alliance with providers) is a 10-item survey measured on a 5 point likert scale for a total possible range of scores from 10 to 50 where higher scores indicate higher connection with provider.	up to 18 months
Survivors' Experiences: Quality of Follow Up Care	Quality of follow-up care using the question: "How would you rate the quality of follow-up care you received in the past 2 years?" This scored from 1 (poor) to 5 (excellent).	up to 18 months
Healthcare Utilization: Number of Visits and Services Used	Healthcare utilization is measured via chart review, and includes use of ancillary services, visits with primary care, visits to urgent care/emergency room.	up to 18 months
Healthcare Utilization: Number of MyChart Visits and Phone Calls	Healthcare utilization is measured via chart review, and includes number of my-chart visits and documented phone calls during 18 month study period.	up to 18 months

Collaborators and Investigators

• Sponsor: University of Wisconsin, Madison
• Collaborators: National Cancer Institute (NCI)
• Investigators: Principal Investigator: Heather Neuman, University of Wisconsin, Madison

Study record dates

Study Major Dates

• Study Start (Actual): November 16, 2022
• Primary Completion (Actual): January 27, 2026
• Study Completion (Actual): January 27, 2026

Study Registration Dates

• First Submitted: November 1, 2022
• First Submitted That Met QC Criteria: November 1, 2022
• First Posted (Actual): November 8, 2022

Study Record Updates

• Last Update Posted (Actual): April 14, 2026
• Last Update Submitted That Met QC Criteria: April 8, 2026
• Last Verified: August 1, 2025

More Information

Terms related to this study

• Keywords: follow up care; low risk; health care delivery
• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Skin Diseases; Breast Diseases; Skin and Connective Tissue Diseases; Breast Neoplasms
• Other Study ID Numbers: 2022-1157; UW22095 (Other Identifier: OnCore ID); SMPH/SURGERY/SURG ONC (Other Identifier: UW Madison); Protocol Version 1/18/2024 (Other Identifier: UW Madison); NCI-2022-10267 (Registry Identifier: NCI Trial ID)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No